Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,734 across all filing types
Latest filing 2021-12-08 Investor Presentation
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
110年12月法人說明會簡報
Investor Presentation Classification · 90% confidence The document is a listing from a public information observation station showing details about a scheduled investor presentation (法人說明會) including date, time, location, and links to presentation materials (PDF files). It is not a full report but rather information about an investor presentation event and related materials. The document length is short (740 characters) and it serves as an announcement or summary of the investor presentation rather than the presentation itself. Therefore, the most appropriate classification is Investor Presentation (IP).
2021-12-08 Chinese
110年12月內部人持股轉讓(事前)
Director's Dealing Classification · 100% confidence The document contains a table detailing a share transfer by a company director (董事本人) and includes information about the number of shares to be transferred, transfer methods, and effective transfer periods. This is a report of a personal share transaction by a company director, which fits the definition of Director's Dealing filings. The document is short and specific to insider share transactions, not a general financial report or announcement. Therefore, the appropriate classification is DIRS (Director's Dealing).
2021-12-03 Chinese
代重要子公司Alvogen Korea Co., Ltd.公告期中股利分派
Notice of Dividend Amount Classification · 100% confidence The document is a short announcement (508 characters) about a dividend distribution decision by the board of a subsidiary company, specifying the dividend amount and the record date. It does not contain detailed financial statements or comprehensive report content. It is an announcement of dividend amount and payment details, fitting the definition of a Notice of Dividend Amount (DIV).
2021-11-30 Chinese
代重要子公司Alvogen Korea Co., Ltd.公告股東臨時會重要 決議事項
Board/Management Information Classification · 95% confidence The document is a brief announcement from a company (1795 美時) regarding an important resolution passed at a shareholders' extraordinary meeting of its subsidiary Alvogen Korea Co., Ltd. The resolution involves amending the company's articles of incorporation. The document is short (501 characters) and serves as a formal disclosure of a corporate governance event rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is an announcement of a board/management-related decision at a shareholder meeting, fitting the category of Board/Management Information (MANG).
2021-11-30 Chinese
代重要子公司Alvogen Korea Co., Ltd.公告召開股東臨時會
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a company (1795 美時) regarding the convening of an extraordinary shareholders' meeting for its important subsidiary Alvogen Korea Co., Ltd. It includes details such as the board resolution date, meeting date, location, and agenda items like amendment of the company's articles of association. The document is short (753 characters) and serves as a formal notification rather than a detailed report or financial statement. It does not contain financial data, management discussion, or audit information. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-11-30 Chinese
泰國Innobic (Asia)與國際藥業創投Aztiq共同取得本公司主 要股東Alvogen Emerging Markets Holdings Limited 100%股權
Major Shareholding Notification Classification · 95% confidence The document is a regulatory announcement from a listed company (1795 美時) disclosing a significant shareholding transaction: the acquisition of 100% equity of a major shareholder (Alvogen Emerging Markets Holdings Limited) by a consortium including Innobic (Asia) and Aztiq. The text details the transaction parties, shareholding percentages, transaction amount, expected completion date, and strategic implications. There are no financial statements, quarterly or annual results, or management discussion of financial performance. The document is a factual disclosure of a major shareholding change, which fits the category of Major Shareholding Notification (MRQ). The document length is short (2313 characters), consistent with a notification rather than a full report. Therefore, the appropriate classification is MRQ with high confidence.
2021-11-26 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.